Rituximab leads to long remissions in patients with chronic immune thrombocytopenia

Khalid Al-Habsi, Murtadha Al-Khabori, Muhanna Al-Muslahi, Anil Pathare, Khalil Al-Farsi, Mohammed Al-Huneini, Sulayma Al-Lamki, Salam Al-Kindi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To assess the response rate and duration of response in patients with chronic immune thrombocytopenia (ITP) receiving rituximab. Methods: We retrospectively analyzed 32 consecutive patients with chronic ITP who were treated in two tertiary centers in Oman. Response assessment was based on the American Society of Hematology criteria. Results: Nineteen patients (59%) had an initial response. However, six of the 19 patients lost their response leaving 13 patients with long-lasting remissions. The median age at diagnosis was 25 years (range 14–58). The median time from diagnosis to rituximab therapy was 21 months. The median follow-up after starting rituximab was 26 months. The overall cumulative response rate was 59% (complete response 44%, partial response 15%) and the median time to respond was 30 days with a response rate of 44% at four weeks. In all responders, the cumulative rate of loss of response was 32% with a median time to lose response of 54 months. Conclusions: The use of rituximab in ITP achieves high response rate and long remission duration. Our study was limited by the small sample size and further larger prospective studies are recommended.

Original languageEnglish
Pages (from-to)111-114
Number of pages4
JournalOman Medical Journal
Volume30
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Idiopathic Thrombocytopenic Purpura
Oman
Sample Size
Rituximab
Prospective Studies

Keywords

  • Blood platelets
  • Idiopathic
  • Purpura
  • Rituximab
  • Thrombocytopenic

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rituximab leads to long remissions in patients with chronic immune thrombocytopenia. / Al-Habsi, Khalid; Al-Khabori, Murtadha; Al-Muslahi, Muhanna; Pathare, Anil; Al-Farsi, Khalil; Al-Huneini, Mohammed; Al-Lamki, Sulayma; Al-Kindi, Salam.

In: Oman Medical Journal, Vol. 30, No. 2, 2015, p. 111-114.

Research output: Contribution to journalArticle

Al-Habsi, Khalid ; Al-Khabori, Murtadha ; Al-Muslahi, Muhanna ; Pathare, Anil ; Al-Farsi, Khalil ; Al-Huneini, Mohammed ; Al-Lamki, Sulayma ; Al-Kindi, Salam. / Rituximab leads to long remissions in patients with chronic immune thrombocytopenia. In: Oman Medical Journal. 2015 ; Vol. 30, No. 2. pp. 111-114.
@article{94f7aebe644b4d829167a0efb9522cad,
title = "Rituximab leads to long remissions in patients with chronic immune thrombocytopenia",
abstract = "Objectives: To assess the response rate and duration of response in patients with chronic immune thrombocytopenia (ITP) receiving rituximab. Methods: We retrospectively analyzed 32 consecutive patients with chronic ITP who were treated in two tertiary centers in Oman. Response assessment was based on the American Society of Hematology criteria. Results: Nineteen patients (59{\%}) had an initial response. However, six of the 19 patients lost their response leaving 13 patients with long-lasting remissions. The median age at diagnosis was 25 years (range 14–58). The median time from diagnosis to rituximab therapy was 21 months. The median follow-up after starting rituximab was 26 months. The overall cumulative response rate was 59{\%} (complete response 44{\%}, partial response 15{\%}) and the median time to respond was 30 days with a response rate of 44{\%} at four weeks. In all responders, the cumulative rate of loss of response was 32{\%} with a median time to lose response of 54 months. Conclusions: The use of rituximab in ITP achieves high response rate and long remission duration. Our study was limited by the small sample size and further larger prospective studies are recommended.",
keywords = "Blood platelets, Idiopathic, Purpura, Rituximab, Thrombocytopenic",
author = "Khalid Al-Habsi and Murtadha Al-Khabori and Muhanna Al-Muslahi and Anil Pathare and Khalil Al-Farsi and Mohammed Al-Huneini and Sulayma Al-Lamki and Salam Al-Kindi",
year = "2015",
doi = "10.5001/omj.2015.24",
language = "English",
volume = "30",
pages = "111--114",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "2",

}

TY - JOUR

T1 - Rituximab leads to long remissions in patients with chronic immune thrombocytopenia

AU - Al-Habsi, Khalid

AU - Al-Khabori, Murtadha

AU - Al-Muslahi, Muhanna

AU - Pathare, Anil

AU - Al-Farsi, Khalil

AU - Al-Huneini, Mohammed

AU - Al-Lamki, Sulayma

AU - Al-Kindi, Salam

PY - 2015

Y1 - 2015

N2 - Objectives: To assess the response rate and duration of response in patients with chronic immune thrombocytopenia (ITP) receiving rituximab. Methods: We retrospectively analyzed 32 consecutive patients with chronic ITP who were treated in two tertiary centers in Oman. Response assessment was based on the American Society of Hematology criteria. Results: Nineteen patients (59%) had an initial response. However, six of the 19 patients lost their response leaving 13 patients with long-lasting remissions. The median age at diagnosis was 25 years (range 14–58). The median time from diagnosis to rituximab therapy was 21 months. The median follow-up after starting rituximab was 26 months. The overall cumulative response rate was 59% (complete response 44%, partial response 15%) and the median time to respond was 30 days with a response rate of 44% at four weeks. In all responders, the cumulative rate of loss of response was 32% with a median time to lose response of 54 months. Conclusions: The use of rituximab in ITP achieves high response rate and long remission duration. Our study was limited by the small sample size and further larger prospective studies are recommended.

AB - Objectives: To assess the response rate and duration of response in patients with chronic immune thrombocytopenia (ITP) receiving rituximab. Methods: We retrospectively analyzed 32 consecutive patients with chronic ITP who were treated in two tertiary centers in Oman. Response assessment was based on the American Society of Hematology criteria. Results: Nineteen patients (59%) had an initial response. However, six of the 19 patients lost their response leaving 13 patients with long-lasting remissions. The median age at diagnosis was 25 years (range 14–58). The median time from diagnosis to rituximab therapy was 21 months. The median follow-up after starting rituximab was 26 months. The overall cumulative response rate was 59% (complete response 44%, partial response 15%) and the median time to respond was 30 days with a response rate of 44% at four weeks. In all responders, the cumulative rate of loss of response was 32% with a median time to lose response of 54 months. Conclusions: The use of rituximab in ITP achieves high response rate and long remission duration. Our study was limited by the small sample size and further larger prospective studies are recommended.

KW - Blood platelets

KW - Idiopathic

KW - Purpura

KW - Rituximab

KW - Thrombocytopenic

UR - http://www.scopus.com/inward/record.url?scp=84926484404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926484404&partnerID=8YFLogxK

U2 - 10.5001/omj.2015.24

DO - 10.5001/omj.2015.24

M3 - Article

AN - SCOPUS:84926484404

VL - 30

SP - 111

EP - 114

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 2

ER -